Amneal Pharmaceuticals (AMRX) Debt to Equity: 2017-2025
Historic Debt to Equity for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -$23.41.
- Amneal Pharmaceuticals' Debt to Equity rose 8.53% to -$23.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.41, marking a year-over-year increase of 8.53%. This contributed to the annual value of -$21.79 for FY2024, which is 117.00% down from last year.
- According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Debt to Equity is -$23.41, which was down 8.11% from -$21.65 recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' Debt to Equity ranged from a high of $128.18 in Q4 2023 and a low of -$41.79 during Q2 2024.
- Moreover, its 3-year median value for Debt to Equity was -$21.65 (2025), whereas its average is -$0.94.
- In the last 5 years, Amneal Pharmaceuticals' Debt to Equity spiked by 789.24% in 2023 and then slumped by 336.08% in 2024.
- Over the past 5 years, Amneal Pharmaceuticals' Debt to Equity (Quarterly) stood at $7.43 in 2021, then spiked by 93.91% to $14.41 in 2022, then soared by 789.24% to $128.18 in 2023, then tumbled by 117.00% to -$21.79 in 2024, then rose by 8.53% to -$23.41 in 2025.
- Its Debt to Equity was -$23.41 in Q3 2025, compared to -$21.65 in Q2 2025 and -$18.51 in Q1 2025.